Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued on Monday, February 4th. They presently have a $24.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 36.52% from the company’s previous close.
The analysts wrote, “We are OW with a $24 PT. The ENHANZE partnerships have recently expanded & include multiple shots on goal, with the reformulation of JNJ’s DARZALEX in P3 studies being most advanced. We believe these partnerships represent multiple value inflection points and, almost irrespective of the outcome of PC, drive our favorable perspective.””
Other research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Tuesday, January 29th. ValuEngine cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 8th. Piper Jaffray Companies reaffirmed a “neutral” rating on shares of Halozyme Therapeutics in a research note on Friday, October 19th. Finally, BidaskClub lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. Halozyme Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $20.17.
Shares of Halozyme Therapeutics stock traded up $0.33 during trading hours on Monday, hitting $17.58. 873,884 shares of the company were exchanged, compared to its average volume of 605,239. Halozyme Therapeutics has a 1 year low of $13.24 and a 1 year high of $21.48. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.09 and a quick ratio of 2.96. The stock has a market capitalization of $2.54 billion, a PE ratio of -31.39 and a beta of 1.75.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, February 21st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.02. The firm had revenue of $60.23 million during the quarter, compared to analysts’ expectations of $59.77 million. Halozyme Therapeutics had a negative return on equity of 31.72% and a negative net margin of 52.90%. Halozyme Therapeutics’s revenue was down 68.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.85 earnings per share. As a group, equities research analysts anticipate that Halozyme Therapeutics will post -0.43 EPS for the current year.
A number of large investors have recently modified their holdings of the business. Bank of Montreal Can raised its holdings in shares of Halozyme Therapeutics by 80.4% in the 4th quarter. Bank of Montreal Can now owns 2,011 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 896 shares during the period. Pacer Advisors Inc. purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter worth about $123,000. Amundi Pioneer Asset Management Inc. purchased a new position in shares of Halozyme Therapeutics in the 4th quarter worth about $140,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Halozyme Therapeutics by 33.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,791 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 2,430 shares during the period. Finally, Pathlight Investors LLC purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $151,000. 83.39% of the stock is currently owned by hedge funds and other institutional investors.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Featured Article: Why do companies pay special dividends?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.